Abstracts Archive - Page 247 of 2425 - ACR Meeting Abstracts

Abstract Number: 0365 • ACR Convergence 2023
Establishing a Multidisciplinary Registry for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Insights into Patient Outcomes and Management Challenges
Stacey Tarvin¹, Amy Rakestraw², Jessica Lee², N. Shaun Matthews³, Susan H. Ballinger² and Christina M. Sparks², ¹Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN, ³Indiana University School of Dentistry, Indianapolis, IN
Background/Purpose: Temporomandibular joint (TMJ) arthritis, a condition frequently overlooked in patients with JIA, can result in joint damage if not promptly treated. Such damage presents…
Abstract Number: 1054 • ACR Convergence 2023
Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT
David Liew¹, Aurora Poon¹, Christopher McMaster², Russell Buchanan¹, Victor Yang¹, Andrew Scott¹ and Claire Owen³, ¹Austin Health, Heidelberg, Australia, ²Austin Health, Pascoe Vale South, Australia, ³Austin Health, Malvern East, Australia
Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…
Abstract Number: 1236 • ACR Convergence 2023
Melanoma Differentiation-Associated Protein-5 in Juvenile Dermatomyositis: A Single Center Cohort
Dawn Gist¹, Sarah Molina², Maria Pereira³, Andrea Ramirez³, Cagri Yildirim-Toruner⁴ and Marietta De Guzman³, ¹Baylor College of Medicine Pediatrics Residency, Houston, TX, ²Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, ³Baylor College of Medicine, Houston, TX, ⁴Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy that causes muscle weakness, rash, vascular changes, or other organ involvement. The phenotypes may vary, and…
Abstract Number: 1181 • ACR Convergence 2023
Real-World Myositis Antibody Frequency and Patient Awareness
Raisa Lomanto Silva¹, shiri keret², Akanksha Sharma³, Tanya Chandra⁴, Siamak Moghadam-Kia¹, Chester V. Oddis⁵ and Rohit Aggarwal⁵, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Bnai Zion, Atlit, Israel, ³UPMC Mercy Hospital, Pittsburgh, PA, ⁴Georgetown University Hospital, Washington, DC, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Myositis-specific antibodies (MSA) represent unique phenotypes in idiopathic inflammatory myopathies (IIM). Myositis-associated antibodies (MAA) most commonly occur in IIM overlap syndromes. MSA and MAA…
Abstract Number: 1060 • ACR Convergence 2023
Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors
Maja Ivanovic¹, Antonia Chan², Miguel Franquiz¹, Sidra Xu³, Carissa Lee³, Muhammad Fazal⁴, Jonathan You¹, Ronald Witteles⁴, Joel Neal⁵, Sean Wu⁴, Sarah Waliany¹ and Han Zhu⁴, ¹Department of Medicine, Stanford University, Stanford, CA, ²Stanford Medical School, Stanford, CA, ³Stanford University, Stanford, CA, ⁴Department of Cardiology, Stanford University, Stanford, CA, ⁵Department of Oncology, Stanford University, Stanford, CA
Background/Purpose: Immune checkpoint inhibitors (ICI) are an increasingly used form of anti-cancer therapy, but they have been associated with a range of cardiac immune-related adverse…
Abstract Number: 1196 • ACR Convergence 2023
Association of Long-Term Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Worsening Symptoms and Structural Changes of Knee Osteoarthritis: An Individual Patient Data Meta-Analysis of Cohort Studies
Zubeyir Salis¹ and Amanda Sainsbury², ¹The University of New South Wales, Kensington, Australia, ²The University of Western Australia, Crawley, Australia
Background/Purpose: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are commonly prescribed for short-term management of symptoms of knee osteoarthritis (KOA), but they are often used long-term, and the…
Abstract Number: 0813 • ACR Convergence 2023
Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 Participants
Mariano Andrés¹, Nalia Domínguez-Lirón², Enrique Calvo-Aranda³, Esther Vicente Rabaneda⁴, Agustín Martínez-Sanchís¹, Francisca Sivera⁵, Diana Peiteado⁶, Alejandro Prada⁷, Blanca Garcia⁸, Basilio Rodríguez⁹, BORIS ANTHONY BLANCO CACERES¹⁰, José Antonio Bernal¹¹, Santos Castañeda¹², Laura Barrio⁷, Sonia Minguez⁹, Mónica Vázquez Díaz¹³, José Miguel Senabre¹¹, Cristina Bohorquez¹⁴, Silvia Gómez-Sabater¹⁵, Rocío Caño-Alameda¹⁵ and Eugenio De Miguel¹⁶, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²Miguel Hernández University, Alicante, Spain, ³Hospital Universitario Infanta Leonor, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Elda General University Hospital, Elda, Spain, ⁶Hospital La Paz, Madrid, Spain, ⁷Hospital Universitario de Torrejón, Madrid, Spain, ⁸Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁹Fundació Althaia, Manresa, Spain, ¹⁰Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹¹Hospital Marina Baixa, Villajoyosa, Spain, ¹²Hospital Universitario de la Princesa, Madrid, Spain, ¹³Hospital Ramon y Cajal, Madrid, Spain, ¹⁴Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ¹⁵Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The prevalence of sonographic monosodium urate (MSU) crystal deposition and inflammation in patients with gout in remission is unknown. In 2022, we reported a…
Abstract Number: 1164 • ACR Convergence 2023
Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study
Carina Soto-Fajardo¹, Sinthia Solorzano Flores¹, Abish Angeles-Acuña¹, Fabian Carranza Enriquez¹, Rosa-Elena Escobar-Cedillo², Saul Renan-Leon², Karina Arias Callejas³, Alejandra Enriquez-Luna², Graciliano Ramon-Diaz² and Carlos Pineda², ¹Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, ²Instituto Nacional de Rehabilitacion, Mexico City, Mexico, ³Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico
Background/Purpose: Immune-mediated myopathies (IMM) are a heterogeneous group of diseases characterized by inflammation and muscle weakness; among their differential diagnoses are the dysferlinopathies, which are…
Abstract Number: 1113 • ACR Convergence 2023
Comparing a Capillary Urate Point-Of-Care Device to Standard Laboratory-based Serum Urate Test for Dose Titration in Gout Patients
Amanuel Kehasse¹, Sayali Dhamne², Michael LaValley³, Jean Liew² and Tuhina Neogi⁴, ¹Boston Medical Center, Boston, MA, ²Boston University, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose: The management of gout remains poor despite the availability of effective medications and recommendation of a treat-to-target treatment strategy using of urate-lowering therapy (ULT).…
Abstract Number: 1180 • ACR Convergence 2023
Machine Learning Approach for the Prediction of anti-MDA5 Positive Dermatomyositis Mortality
Xinlei Liu¹, Fumin Qi², Wei Wei¹ and Yin Zhao¹, ¹Tianjin Medical University General Hospital, Tianjin, China, ²Tianjin Medical University, Tianjin, China
Background/Purpose: We describe a single-center clinical cohort of MDA5 positive dermatomyositis(DM) in China and apply a machine learning approach to predict the risk of mortality…
Abstract Number: 0786 • ACR Convergence 2023
A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort
Anna Arar, Diane L. Kamen, Paul Nietert and Melissa Cunningham, Medical University of South Carolina, Charleston, SC
Background/Purpose: Manifestations of systemic lupus erythematous (SLE) vary in severity and presentation; lupus nephritis (LN) affects up to half of SLE patients and confers a…
Abstract Number: 1047 • ACR Convergence 2023
Infrared Thermography Imaging Discriminates Between Inflamed and Non-inflamed Joints
Maria I. ("Maio") Danila¹, Giovanna Rosas², Fenglong Xie², Jeffrey R Curtis³, Kiara Aaron², Stephanie Ford² and Laura Hughes⁴, ¹University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁴University of Alabama at Birmingham; East Alabama Medical Center, Birmingham, AL
Background/Purpose: Infrared thermography (IRT) is an emerging technology that has the potential to rapidly assist in identifying joint inflammation in patients with joint symptoms. However,…
Abstract Number: 1206 • ACR Convergence 2023
Self-Perceptions of Aging and Physical Activity in Older Adults with Arthritis: Does General Health Matter?
Sarah Lieber¹, Jerad Moxley², Lisa Mandl¹, M. Carrington Reid² and Sara Czaja², ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Negative self-perceptions of aging are generally associated with decreased physical function in older adults. Whether self-perceptions of aging (i.e., "awareness of age-related change" including…
Abstract Number: 1081 • ACR Convergence 2023
Clinical Consequences of Infliximab Immunogenicity and the Impact of Proactive Therapeutic Drug Monitoring: Secondary Analyses of a Randomised Clinical Trial
Marthe Brun¹, Kristin Hammersbøen Bjørlykke², Johanna E. Gehin³, David John Warren³, Rolf A. Klaasen³, Joseph Sexton¹, Øystein Sandanger⁴, Tore Kvien¹, Cato Mørk⁵, Jørgen Jahnsen², Nils Bolstad³, Kristin Kaasen Jørgensen², Espen Haavardsholm¹, Guro Goll¹ and Silje Watterdal Syversen¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ³Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴Section of Dermatology, Oslo University Hospital, Oslo, Norway, ⁵Akershus Dermatology Center, Lørenskog, Norway
Background/Purpose: Formation of anti-drug antibodies (ADAb) to biological drugs is a clinical problem. Proactive therapeutic drug monitoring (TDM) allows for timely detection of ADAb and…
Abstract Number: 1076 • ACR Convergence 2023
Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study
Olga Rusinovich¹, Enrique Calvo-Aranda², Claudia Maria Gomez², Patricio Cardoso Peñafiel², Pilar Navarro Alonso³, Miguel Cantalejo Moreira⁴, Alberto Diaz y Oca³, Pablo Navarro⁵, Maria Machattou⁵, Maria Alonso⁵, Carlota Navarro⁵, Carolina Merino⁵, Hilda Godoy⁶, Maria Carmen Barbadillo Mateos⁷, Carlos Isasi⁵, Maria Perez Ferro⁸, Jessica Polo⁹, Veronica Garcia¹⁰, Jose Luis Andreu-Sánchez¹¹, Jose Campos¹² and Jesus Sanz¹³, ¹Puerta de Hierro Majadahonda University Hospital, Boadilla del Monte, Spain, ²Hospital Universitario Infanta Leonor, Madrid, Spain, ³Fuenlabrada University Hospital, Madrid, Spain, ⁴Hospital Universitario de Fuenlabrada, Madrid, Spain, ⁵Puerta de Hierro Majadahonda University Hospital, Madrid, Spain, ⁶Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁷Public, Madrid, Spain, ⁸Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁹Rey Juan Carlos University Hospital, Madrid, Spain, ¹⁰Ramon y Cajal University Hospital, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹²Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ¹³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Rituximab (RTX) is a murine/human chimeric monoclonal antibody directed against the CD20 receptor expressed on pre-B and mature B cells. Rituximab is used effectively…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].